Cardiff Oncology Inc expected to post a loss of 17  cents a share - Earnings Preview

Cardiff Oncology

21/02/2022 11:06

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
23 (estimated). 
    * The San Diego California-based  company is expected to
report  a
64.3% decrease in revenue to $42.5 thousand from $119 thousand a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cardiff Oncology
Inc is
for a loss of 17 cents per share. For the same quarter last
year, the company reported a loss of 19 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $22​, about 86.8% above​ its last closing price
of $2.91. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.17       -0.17      -0.17     Met     0
 Jun. 30 2021  -0.15       -0.15      -0.17     Missed  -13.5
 Mar. 31 2021  -0.16       -0.15      -0.14     Beat    5.1​
 Dec. 31 2020  -0.15       -0.14      -0.19     Missed  -35.7
 ​​Sep.        -0.19       -0.19      -0.19     Met     -1.8
 30 2020                                                
 Jun. 30 2020  -0.24       -0.24      -0.51     Missed  -112.5
                                                        ​
 Dec. 31 2019  -0.79       -0.57      -0.51     Beat    11.3
 This summary was machine generated February 21 at 11:06 GMT. 
All figures in US dollars  unless otherwise stated